Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common heart drug improve how the heart relaxes?

NCT ID NCT07157527

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether the drug sacubitril/valsartan (Entresto) can improve the heart's ability to relax in people with heart failure and reduced pumping strength. Researchers will use ultrasound to measure changes after six months of treatment. The study involves 70 adults from two heart centers in Egypt.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sacubitril/valsartan (Entresto)
What this could lead to
If successful, this could show that sacubitril/valsartan improves heart relaxation in patients with heart failure and reduced pumping ability, potentially guiding better treatment.
What could go wrong
This is a small, early-stage observational study with only 70 participants. It may not prove long-term benefits, and results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study enrolls 70 patients characterized by a high prevalence of comorbidities including diabetes mellitus, hypertension, obesity, chronic kidney disease, dyslipidemia, and smoking, reflecting the typical clinical profile of Egyptian HFrEF patients. The median age is younger compared to Western cohorts, with patients presenting advanced heart failure symptoms and poorer functional status. Inclusion criteria require participants to tolerate and comply with ARNI therapy and exclude those with significant mitral valve disease, atrial arrhythmias, pacemakers, or poor echocardiographic windows. Comprehensive demographic and clinical data are collected, including sex, NYHA functional class, baseline medications, and heart failure subclassification. This population thus represents a real-world, high-risk group vulnerable to adverse heart failure outcomes, suitable for studying ARNI's effects on diastolic function and overall cardiac remodeling.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with HFrEF (LVEF \< 35%) * Able to tolerate and comply with ARNI therapy * Patients on Guideline-Directed Medical Therapy (GDMT) for heart failure Exclusion Criteria: * Patients with contraindication to ARNI therapy * Patients with poor echocardiographic window * Patients non-compliant with medication or follow-up * Patients with mitral significant lesion or mitral prosthesis. * Patients with atrial arrhythmia or on pacemaker

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Left ventricular diastolic function

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.